MARKET

PLX

PLX

Protalix Biother
AMEX
1.640
-0.020
-1.20%
Pre Market: 1.650 +0.01 +0.61% 06:26 09/27 EDT
OPEN
1.660
PREV CLOSE
1.660
HIGH
1.670
LOW
1.630
VOLUME
44
TURNOVER
--
52 WEEK HIGH
3.550
52 WEEK LOW
1.000
MARKET CAP
117.39M
P/E (TTM)
50.15
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at PLX last week (0918-0922)?
Weekly Report · 1d ago
Weekly Report: what happened at PLX last week (0911-0915)?
Weekly Report · 09/18 11:30
Protalix Biother: Initial statement of beneficial ownership of securities
Press release · 09/16 14:25
Protalix BioTherapeutics Appoints Eliot Richard Forster To Succeed Zeev Bronfeld As Chairman
NASDAQ · 09/12 11:04
Protalix BioTherapeutics Appoints Eliot Richard Forster As Chairman Of Its Board, Effective As Of September 14, 2023
Benzinga · 09/12 10:54
Weekly Report: what happened at PLX last week (0904-0908)?
Weekly Report · 09/11 11:28
Protalix BioTherapeutics Stock Is A Hold Pending Successful Commercialization Of Elfabrio
Seeking Alpha · 09/06 12:12
Protalix BioTherapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
PR Newswire · 09/06 10:50
More
About PLX
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Its ProCellEx platform is being used to manufacture approved and marketed product, Elelyso, for the treatment of Gaucher disease. The Company’s ProCellEx is its proprietary platform used to produce and manufacture recombinant proteins through plant cell-based expressions in suspension. Protalix’s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target pharmaceutical markets, including the product candidates, such as PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases, and others.

Webull offers kinds of Protalix Biotherapeutics Inc stock information, including AMEX:PLX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PLX stock methods without spending real money on the virtual paper trading platform.